Evaluation of efficacy of new spectroscopic biomarkers for the detection of early-stage pancreatic cancer.
Clinical registry of breast cancer patients who have been treated with trastuzumab (Herceptin®), lapatinib (Tyverb®), bevacizumab (Avastin®) and/or everolimus (Afinitor®).
International clinical registry of patients with chronic myeloid leukaemia.
System of informational support for the Cervical Cancer Screening Programme in the Czech Republic.
Clinical registry of patients with chronic lymphocytic leukaemia (CLL).
Clinical registry of colorectal cancer (CRC) patients who have been treated with cetuximab (Erbitux®), bevacizumab (Avastin®) and/or panitumumab (Vectibix®).
Clinical registry monitoring cases of bladder cancers treated with cystectomy and consecutive treatment.
Clinical registry of patients with acute myeloid leukaemia (AML).
Non-interventional, multicentre, retrospective and prospective study of patients with brain tumours, who have been treated in the Czech Republic according to the common clinical practice.
Clinical registry of haemato-oncological patients in which antimycotic therapy has been administered.
Clinical registry of patients with chronic myeloid leukaemia (CML).
Registry of EGFR mutation testing results in patients with non-small-cell lung cancer (NSCLC) in the Czech Republic.
System of informational support for the Colorectal Cancer Screening Programme in the Czech Republic.
Central Czech registry of morphologically examined breast cancers, with particular emphasis on the collection of data regarding the examination of HER2/neu status in the Czech population.
System of informational support for the Breast Cancer Screening Programme in the Czech Republic.
Clinical registry of melanoma patients who have been treated with dabrafenib (Tafinlar®), ipilimumab (Yervoy®), nivolumab (Opdivo®), trametinib (Mekinist®), pembrolizumab (Keytruda®) and/or vemurafenib (Zelboraf®).
Clinical registry of patients with myeloproliferative disorders.
Český registr neuroendokrinních nádorů.
International clinical registry gathering data on the management of patients with non-small cell lung cancer (NSCLC) who were diagnosed at the clinical stage III.
Clinical registry of ovarian cancer patients who have been treated with bevacizumab (Avastin®) and/or olaparib (Lynparza®).
Parametric collection of basic clinical data on paediatric cancer patients, interactive analytical reports.
Clinical registry of pleural mesothelioma patients who have been treated with pemetrexed (Alimta®).
Clinical registry monitoring the epidemiology of gastrointestinal stromal tumours (GIST) as well as therapeutic approaches and treatment results in GIST patients in the Czech Republic and Slovakia.
Clinical registry of kidney cancer patients who have been treated with bevacizumab (Avastin®), everolimus (Afinitor®), pazopanib (Votrient®), sorafenib (Nexavar®), sunitinib (Sutent®) and/or temsirolimus (Torisel®).
Clinical registry of patients suffering from sellar tumours.
Clinical registry of non-small cell lung cancer (NSCLC) patients who have been treated with bevacizumab (Avastin®), erlotinib (Tarceva®), gefitinib (Iressa®), pemetrexed (Alimta®), afatinib (Giotrif®) and/or nintedanib (Vargatef®).